20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Pneumococcal
Vaccine-Naïve Adults 60 Years of Age and Older in Japan, Korea, and Taiwan. Final Report: A Phase 3, Randomized, Double-Blind, Third-Party-Unblinded Trial to Evaluate the Safety and
Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults 60 Years of Age and Older in Japan, Korea, and Taiwan.